Kornimate/medical-research-clean huggingface dataset:
supplementing neuro-energy to aid cognition

Conditions: Alzheimer Disease and Related Dementias (ADRD)

Summary: it is projected that by 2030, one in every five americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. a key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. this study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging.

there are now close to six million people in the unites states living with dementia and this number is only expected to grow as the population continues to age. the current lack of effective treatments for alzheimer's disease (ad) speaks to the need to better understand the multiple factors that contribute to this complex disease. there is growing evidence that age-related metabolic dysfunction in the brain plays a role in the disease's etiology. this concept has led to treatments aimed at improving brain energy production. notably, ketogenic dietary supplements have been shown to increase brain ketone metabolism and improve cognitive performance in ad patients. however, the overall benefits to brain metabolism in the ad brain are unknown given the complexity of imaging both oxygen and glucose metabolism in a single session by positron emission tomography (pet). taking advantage of hybrid pet/mr imaging, this study will combine pet and mri methods to investigate the effects of a ketogenic supplement on brain oxygen and glucose metabolism in ad patients.

Eligibility criteria:
inclusion criteria - healthy participants: males and females, age 21 - 80 years, bmi of 18.5-30 inclusion criteria - alzheimer's disease participants: positive amyloid and tau biomarkers (as noted by pet imaging, cerebrospinal fluid or blood), mild cognitive impairment or mild-to-moderate dementia, bmi of 18.5-30 exclusion criteria: contraindications to mri (claustrophobia, metal implants, pacemakers, etc.), pregnant or breastfeeding women, neurological disease (healthy participants only), mental illness, overt cardio- or neurovascular disease, recent participation in any procedure(s) involving radioactive agents

Keywords: pet/mr, keytone supplement, brain energy metabolism
brightening cream and lasers in post-sclerotherapy hyperpigmentation

Conditions: Hyperpigmentation; Varicosis

Summary: the treatment of leg veins and varicosis with sclerotherapy is one of the most frequently performed medical intervention in the western world. the most common local side effects of this treatment are hyperpigmentations caused by hemosiderin deposition in the skin as well as post inflammatory hyperpigmentation. although skin hyperpigmentation after sclerotherapy is a common over several months up to years lasting side-effect with a strong aesthetic impact, scanty data exist about treatment options. quality-switched (qs) lasers are efficient in the removal of exogenous and endogenous pigments, such as tattoos as well as epidermal and dermal melanin deposits. the laser light is absorbed by pigment particles, leading to a fragmentation of these particles by a photothermal and photoacoustic effect. smaller particles can be then phagocyted by macrophages, and transported via the lymphatic system into the lymph nodes. furthermore, the positive effect of qs lasers in the management of cutaneous siderosis in stasis dermatitis and after sclerotherapy has been described in several cases. triple cream including hydroquinone, tretinoin and a topical corticosteroid (eg dexamethasone), is the first line therapy in the treatment of post inflammatory hyperpigmentation. this randomized controlled study aims to evaluate the efficiency of two well-known depigmentation methods (qs laser and triple cream) for treatment of post sclerotherapy hyperpigmentation, compared with a control group performing no treatment.


Eligibility criteria:
inclusion criteria: * fitzpatrick skin type i-iv * presence of at least 1 postinflammatory hyperpigmentation after sclerotherapy exclusion criteria: * history of adverse events related to short-pulsed laser therapy * pregnant or breast-feeding women * intention to become pregnant during the course of the study * history of intolerance or allergic reaction to triple cream or one of its ingredients * prior treatment with parenteral gold therapy * inability to understand the study content

Keywords: laser nd:yag
pain relief and and peripheral perfusion index during erector spinae block

Conditions: Block; Block, Fascicular; Spinae

Summary: the primary endpoint of this study is to compare the pain relief and peripheral perfusion index when local anesthetics injected in different final target area during lumbar erector spinae block the secondary endpoint of this study is to compare the procedure related pain

the erector spinae plane block (espb) is a less invasive, safer, and technically easy alternative procedure to conventional neuraxial anesthetic techniques. in contrast to common neuraxial techniques such as paravertebral and epidural injections, the espb targets an interfascial plane which is far from the spinal cord, root, and pleura. first applied to thoracic neuropathic pain, currently espb is being applied to postoperative pain control and includes variable clinical situations. in the abdomen and thoracic wall, thoracic espb can be applied for pain control after cardiac surgery, video-assisted thoracic surgery, laparoscopic cholecystectomy, and thoracotomy. recently, favorable postoperative pain control after lumbar spinal or lower limb surgeries has been reported with lumbar espb. in addition, espb has also been used for chronic pain conditions in the upper and lower extremities. the final target area of espb of cervical, thoarcic, and lumbar regiona is transverse process. once the needle contact the tip of the transverse process, local anesthetics is injected subsequentely. however, contacting the bony structure with the needle can generage procedure related pain. if espb can be performed without touching the transverse process, the satisfaction of patient would be increased. actually, intertransverse ligament, which is visibe by ultrasound, is present between transverse process. therefore, if local anesthetics is injected after targeting intertransverse ligament, same effect of pain relief with tarting of transverse process of espb is uncertain

Eligibility criteria:
inclusion criteria: * lumbar disc herniation * lumbar foraminal stenosis * lumbar central stenosis * lumbar spondylolisthesis * numerical rating scale \> 4 * back pain functional scale \< 45 * duration of pain \> 1 mon * patients who can fully understand all items described in back pain functional scale exclusion criteria: * allergy to local anesthetics or contrast medium * pregnancy * spine deformity * prior history of lumbar spine surgery * no previous lumbar mri or ct * patients with coagulation abnormality
long-term observational study to evalution the safety and efficacy of furestem-ad inj.

Conditions: Atopic Dermatitis

Summary: observational study to assess the safety and efficacy of furestem-ad lnj. in moderate to atopic dermatitis

this is a observational study, single center, open label, study of safety and efficacy of furestem-ad inj. in subjects with moderate to severe atopic dermatitis.

Eligibility criteria:
inclusion criteria: * subjects participating in this observational study originally participated in study furestem-ra inj.\[nct02221258\] * subject who understands and voluntarily sign an informed consent form exclusion criteria: * in case follow-up is not possible from end of clinical trial phase 1/2a to end of this study period

Keywords: furestem-ad inj. stem cells
trns in anterior cingulate cortex reduces craving over dual pathology patients

Conditions: Substance Use Disorder; Attention Deficit Disorder With Hyperactivity; Bipolar Disorder; Schizophrenia; Personality Disorder

Summary: the purpose of this study is to study the efficacy and security of noninvasive brain stimulation as a new approach for patients with substance use disorders (suds) plus other psychiatric conditions like adhd, schizophrenia, bipolar disorder, etc.

background: there is an intimate relationship between addictive behaviors and other mental disorders, proven by clinical practice and many epidemiological studies, genetic and neuroscience. this gives risk to the diagnosis of dual pathology: an addiction and another mental disorder. functional neuroimaging studies have shown that anterior cingulate cortex is associated with substance´s dependence and craving. transcranial random noise stimulation (trns) stimulates parts of the brain and can change it´s activity. researchers are interested in reduce cravings for substance dependence on patients with dual pathology using trns in anterior cingulate cortex. aims: to determine whether trns in anterior cingulate cortex can reduce craving over dual pathology patients.

Eligibility criteria:
inclusion criteria: * \> 18 years old and less than 60 years * best-practice diagnosed dual pathology * diagnosed since at least two years prior to enrollment. * abuse more than 2 substances exclusionc riteria: * serious visual and hearing loss * brain injury following cranial trauma * other neurological disorders like parkinson, me, headache, etc. * birth trauma * mental retardation * pregnant

Keywords: substance use disorder attention deficit disorder with hyperactivity schizophrenia bipolar disorder personality disorder
examining the effects of an improvisation group

Conditions: Anxiety; Depression; Self Concept Alteration; Social Support

Summary: this study is taking place to examine the preliminary effects of improvisational therapy (improv group) on social anxiety for youth at the youth wellness centre (ywc). the improv group will run for 12-weeks as a drop-in group. a typical session will begin with stretching, simple breathing and an activity to promote group cohesion. following this, improvisation games and activities will be introduced with the goal of promoting the following skills: assertiveness, acceptance, problem solving, co-operate skills, non-verbal communication, mindfulness, and memory. youth who consent to the study will be asked to complete a set of brief questionnaires the first time they attend one of the sessions. youth who have attended at least 3 sessions will be asked again to complete questionnaires following the completion of week 12 session. youth will also rate their anxiety and distress on a simple rating scale at the beginning and end of each session. additionally, all participants (who have attended three or more sessions) will be invited to complete a 30 to 45 minute qualitative interview following the 12 week session. participants are predicted to show a decrease in social anxiety, generalized anxiety and depression symptoms, and an increase in self-esteem, and perceived social support.


Eligibility criteria:
inclusion criteria: * help-seeking youth * ages 17-25 exclusion criteria: * will not be excluded on the basis of mental health or addiction concerns
bi 671800 in asthmatic patients on inhaled corticosteroids

Conditions: Asthma

Summary: to investigate the effectiveness and safety of bi 671800 given in the morning (am), evening (pm) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.


Eligibility criteria:
inclusion criteria: 1. signed informed consent consistent with international conference on harmonisation (ich) - good clinical practice (gcp) (ich-gcp) 2. three month history of reversible (12% with 200 ml) asthma according to \[global initiative for asthma (gina)\] with following spirometry at randomization:forced expiratory volume in 1 second (fev1) 60%-85%. 3. stable inhaled corticosteroid (ics) dose 3 months prior to screening. 4. diagnosis of asthma prior to 40 years. 5. asthma control questionnaire (acq) at least 1.5 at randomization. 6. male or female, 18 to 65 years. 7. non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine screen. 8. able to perform pulmonary function test (pft). exclusion criteria: 1. significant diseases other than asthma or allergic rhinitis. 2. hepatic transaminases or total bilirubin greater than 1.5 upper limit of normal (uln). 3. hospitalizations for asthma or asthma related intubation within 3 months. 4. uncontrolled asthma on ics + another controller. 5. respiratory tract infection or exacerbation within 4 weeks. 6. fev1 less than 40%, more than 12 puffs of short acting beta agonists (saba) on more than two consecutive days or asthma exacerbation during the run-in period. 7. participation in another interventional study. 8. pregnant or nursing women. 9. women of child bearing potential nor using appropriate methods of birth control as defined by protocol.
apply the (mytransition) app in transition

Conditions: Chronic Health Condition

Summary: moving from child care to adult care is a hard time for patients and their families. parents of children with chronic conditions say they need more support around the time of changing care. care providers say they do not have the tools to provide smooth transitions or help their patients manage their own health. this study is to see if a smart-phone-based app (named mytransition) can improve healthcare transition experiences and health outcomes for youth, compared to usual care.

transition to adult care is an unavoidable and challenging period for patients and their families, and comes with adverse outcomes in experience of care, population health, and costs. parents of children with chronic conditions report a greater need for support around the time of healthcare transition. providers report neither having the tools nor appropriate resources to foster smooth transitions for patients and their families. we hypothesize that an app-based transition toolkit (named mytransition) designed to support youth moving from child to adult care can improve their experiences and lead to better health. the main objective of this study is to collect information to design a large multi-centre randomized control trial to assess implementation of the mytransition app including recruitment, completion of follow-up, and scale-ability of the intervention. the secondary objective is to assess the feasibility and potential effect of the mytransition app-based transition toolkit for improving health of youth (quality of life), healthcare transition experience, and achievement of health and life goals.

Eligibility criteria:
inclusion criteria: * attending participating clinic at mcmaster children's hospital * diagnosed with chronic health condition * must be able to utilize the intervention tool * must be able to read and understand english exclusion criteria: * dependence on caregivers in areas of daily functioning, self-care and/or communication * inability to lead or provide own care * enrolled in a potentially confounding trial

Keywords: transition improved patient outcomes rct child health empower youth
study of arginine and nitric oxide in patients with diabetes

Conditions: Ketosis Prone Diabetes

Summary: this study will test the effect of citrulline versus placebo supplementation in ketosis-prone diabetes (kpd) patients on arginine and nitric oxide production and on glucose- and arginine-stimulated insulin secretion and arterial flow-mediated dilation.

both arginine and its derivative nitric oxide (no) have been implicated in the regulation of glucose homeostasis. arginine is a β cell secretagogue, potentiating glucose stimulated insulin secretion. further, it has been shown that glucose can stimulate no production in primary β cells, and no then enhances insulin secretion. on the other hand, because the only known fate of citrulline is its conversion to arginine, citrulline supplementation could be a more efficient and safe way to increase intracellular arginine. compared to enteral arginine, citrulline administration to healthy humans elicited a greater increase in plasma arginine and no products, suggesting a greater increase in cellular arginine availability for no synthesis. therefore dietary citrulline supplementation will result in greater arginine availability and no synthesis than arginine supplementation per se in kpd patients. in addition, because the consequences of diminished no production in usual type 2 diabetes includes vascular dysfunction, an overall increase in no production in response to citrulline supplementation will result in an improvement in vascular function assessed by arterial flow-mediated dilation

Eligibility criteria:
inclusion criteria: * new onset (defined as receiving a diagnosis within the past 1 year) diagnosis of unprovoked" a-β+ ketosis-prone diabetes * aged 20-65 years * in good health except for diabetes without clinical evidence of micro- or macrovascular complications by history, physical exam and blood chemistries exclusion criteria: * chronic or acute illness * history of myocardial infarction or coronary artery disease or stroke, * renal insufficiency (egfr \<90ml/min/1.73m2; \<30 mg albumin / g creatinine in urine) * abnormal liver, thyroid, gonadal or adrenal functions * on medications other than metformin, * on any hormonal replacement therapy * pregnancy
acalabrutinib in combination with acp-319, for treatment of chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: this study is evaluating the safety and efficacy of the combined use of acalabrutinib and acp-319, for the treatment of chronic lymphocytic leukemia (cll)


Eligibility criteria:
inclusion criteria: * men and women ≥ 18 years of age with a confirmed diagnosis of cll, which has relapsed after, or been refractory to, ≥ 1 previous treatments for cll; however, subjects with 17p deletion are eligible if they have relapsed after, or been refractory to, 1 prior treatment for cll. * eastern cooperative oncology group (ecog) performance status of ≤ 2. * agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children. exclusion criteria: * prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years. * a life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib and/or acp-319, or put the study outcomes at undue risk. * significant cardiovascular disease. * malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. * any immunotherapy within 4 weeks of first dose of study drug. * for subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s). * history of prior allogeneic bone marrow progenitor cell or solid organ transplantation. * ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of cll or other conditions. note: subjects may be using topical or inhaled corticosteroids as therapy for comorbid conditions. * central nervous system (cns) involvement by cll. * grade ≥ 2 toxicity (other than alopecia). * known history of human immunodeficiency virus (hiv) or active infection with hepatitis c virus (hcv) or hepatitis b virus (hbv) or any uncontrolled active systemic infection. * uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura. * absolute neutrophil count (anc) \< 0.75 x 109/l or platelet count \< 50 x 109/l unless due to disease involvement in the bone marrow. * creatinine \> 1.5 x institutional upper limit of normal (uln); total bilirubin \> 1.5 x uln (unless due to gilbert's disease); and aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 2.5 x uln unless disease related. * significant screening ecg abnormalities including left bundle branch block, 2nd degree av block type ii, 3rd degree block, grade 2 or higher bradycardia, and qtc \> 480 msec.

Keywords: bruton tyrosine kinase inhibitor btk
effect of life kinetik training on lower limb coordination in ataxic patients

Conditions: Multiple Sclerosis; Ataxia

Summary: coordination is essential for the performance of most daily motor activities. coordination problems are common in ms patients. one of the most commonly reported symptoms is dysmetria (limb ataxia). ataxia is thought to occur in about 80% of ms patients. it leads to limitations in daily life activities. aim of study: to investigate the effect of life kinetik training on lower limb coordination in ms patients with ataxia.

methods: thirty remitting relapsing multiple sclerosis (rrms) patients from both sexes with ataxic symptoms, will be recruited from multiple sclerosis specialized clinic in the neurology department, faculty of medicine, cairo university with edss score will be ranged from 2 to 4 and sara score will be ranged from 1 to 10. lower extremity motor coordination test (lemocot) will be used to assess lower limb motor coordination. they will be randomly assigned into two equal groups; control group (gi) will receive selected physical therapy program and study group (gii) will receive same program of (gi) in addition to life kinetik training.

Eligibility criteria:
inclusion criteria: * ms from both sexes * patients' age will be ranged from 20 to 45 years * expanded disability scale (edss) score ranging from "two" to "four" exclusion criteria: * patients with ataxia caused by other cause rather than ms * patients with other neurological disease or orthopedic deformities may affect movement * patients with cardiovascular and pulmonary diseases that make exercise unsafe * patients with cognitive impairment or psychiatric disorders

Keywords: multiple sclerosis ataxia coordination life kinetic exercises
dietary phosphorus load and postprandial serum phosphate in hd patients

Conditions: Hemodialysis

Summary: this study is to investigate the acute postprandial effect of a modified versus standard low phosphorus diet on serum phosphate, potassium and intact parathyroid levels in prevalent hemodialysis (hd) patients

background: potential dietary strategies for controlling hyperphosphataemia include the use of protein sources with lower phosphorus bioavailability such as pulses and nuts, focus on phosphorus to protein ratios and the avoidance of all phosphate additives. method: controlled crossover feeding study in 8 hd patients. on one day, participants were directly observed eating a standard low phosphorous diet and on the other day, a modified low phosphorus diet. the modified diet included beef and less dairy, with a lower phosphorus to protein ratio, as well as plant-based protein, whole grains, pulses and nuts containing phytates which reduces phosphorus bioavailability. both diets were tailored for each participant to provide 1.1g protein/kg ideal body weight. participants provided fasting bloods before breakfast, a pre-prandial sample before lunch and samples at one hour intervals for the four hours after the meal, for analysis of phosphate, potassium and intact parathyroid hormone (ipth).

Eligibility criteria:
inclusion criteria: * \> 18 years of age; * on dialysis for \> 3 months; * pre-dialysis serum phosphate \< 2.5 mmol/l and * serum potassium \< 6.3 mmol/l on most recent routine monthly blood test; * urinary outputs of \< 200 ml/day by self-report; * being in their usual state of health exclusion criteria: * history of diabetes mellitus * history of parathyroidectomy * history of calciphylaxis

Keywords: dietary phosphorus hyperphosphatemia hyperkalaemia phytate hemodialysis